Join to view full profile
9900 W Colonial DrOcoee, FL 34761
Phone+1 321-843-7440
Fax+1 321-843-7497
Dr. Najera is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Jose Najera, MD, is an oncologist based in Ocoee, FL, with specialized expertise in hematologic oncology and various related conditions. He completed his fellowship in Hematology and Medical Oncology at Orlando Health, following a residency in Internal Medicine at the University of Texas Health Science Center. Currently employed at Orlando Health - Health Central Hospital, he has previously held positions including Assistant Professor at Oklahoma State University Medical Center and Hematologist/Oncologist roles in Oklahoma. Dr. Najera has contributed significantly to medical literature, with publications addressing topics from cancer treatment to chronic kidney disease. He has been recognized with multiple CMS Meaningful Use Stage Certifications from MOSAIQ and Elekta.
Education & Training
Orlando HealthFellowship, Hematology and Medical Oncology, 2010 - 2013
University of Texas Health Science Center San Antonio Joe and Teresa Lozano Long School of MedicineResidency, Internal Medicine, 2007 - 2010
Universidad de MonterreyClass of 2007
Certifications & Licensure
FL State Medical License 2025 - 2028
OK State Medical License 2013 - 2027
TX State Medical License 2012 - 2027
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification MOSAIQ, Elekta - IMPAC Medical Systems, Inc., 2014-2015, 2017
- CMS Meaningful Use Stage 1 Certification MOSAIQ, Elekta - IMPAC Medical Systems, Inc., 2014-2015, 2017
- CMS Meaningful Use Stage 1 Certification MOSAIQ EMR, Elekta, 2013
Publications & Presentations
PubMed
- 563 citationsNeoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma.Sapna P Patel, Megan Othus, Yuanbin Chen, G Paul Wright Jr, Kathleen J Yost
The New England Journal of Medicine. 2023-03-02 - 8 citationsA Phase II Study Evaluating Orteronel, an Inhibitor of Androgen Biosynthesis, in Patients With Androgen Receptor (AR)-Expressing Metastatic Breast Cancer (MBC).Denise A. Yardley, Robyn R. Young, Kerin B. Adelson, Andrea Silber, Jose E. Najera
Clinical Breast Cancer. 2021-10-28 - 4 citationsCohort study with patients older than 80 years with stage 5 chronic kidney failure on hemodialysis vs conservative treatment: Survival outcomes and use of healthcare r...Alicia García Testal, Rafael García Maset, Victoria Fornés Ferrer, Antonio José Cañada Martínez, Sonia Fernández Fandos
Therapeutic Apheresis and Dialysis. 2021-02-01
Committees
- President, Oklahoma Society of Clinical Oncology 2018 - 2025
Research History
- Principal Investigator2017 - Present
- Head of researchHead of research for Cancer Centers of Southwest Oklahoma2016 - 2025
Other Languages
- Spanish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
